Table 1

Resistance profilesa of staphylococcal isolates (n = 850) from eyes and other clinical sources in health and disease

Antimicrobial Agent (n = 18)b
Percentage of Resistancec Displayed by



S. aureus n = 513 (%)
Clinical S. arueus n = 338(%)
Carrier S. arueus n = 175 (%)
Coagulase-negative Staphylococci (CNS) n = 337 (%)
Clinical CNS n = 237 (%)
Carrier CNS n = 100 (%)

Amikacin
65 (12.7)
47 (13.9)
18 (10.3)
27 (8.0)
27 (11.4)
0 (0.0)
Ampicillin
413 (80.5)
275 (81.4)
138 (78.8)
241 (71.5)
183 (77.2)
58 (58.0)
Cefazolin
190 (37.0)
131 (38.8)
59 (33.7)
80 (23.7)
64 (27.0)
16 (16.0)
Cephalexin
237 (46.2)
165 (48.8)
72 (41.1)
86 (25.5)
68 (28.7)
18 (18.0)
Cephotaxime
207 (40.3)
145 (42.9)
62 (35.4)
78 (23.2)
68 (28.7)
16 (16.0)
Chloramphenicol
22 (4.3)
16 (4.7)
6 (3.4)
17 (5.0)
12 (5.1)
5 (5.0)
Ciprofloxacin
103 (20.1)
81 (24.0)
22 (12.6)
75 (22.2)
56 (23.6)
19 (19.0)
Clindamycin
79 (15.4)
60 (17.7)
19 (10.9)
71 (21.1)
56 (23.6)
15 (15.0)
Co-trimoxazoled
256 (50.0)
175 (51.8)
81 (46.3)
136 (40.3)
104 (43.9)
32 (32.0)
Fusidic acid
18 (3.5)
14 (4.1)
4 (2.3)
12 (3.6)
8 (3.4)
4 (4.0)
Gentamicin
172 (33.5)
122 (36.1)
50 (28.6)
90 (26.7)
72 (30.4)
18 (18.0)
Imipenem
136 (26.5)
97 (28.7)
39 (23.3)
68 (20.2)
54 (22.8)
14 (14.0)
Methicilline
180 (35.1)
128 (37.9)
52 (29.7)
76 (22.5)
63 (26.6)
13 (13.0)
Penicillin G
472 (92.0)
313 (92.6)
159 (90.9)
303 (89.9)
222 (93.7)
81 (81.0)
Rifampin
97 (18.9)
68 (20.1)
29 (16.6)
41 (12.2)
33 (13.9)
8 (8.0)
Roxithromycin
146 (24.6)
103 (30.5)
43 (24.6)
53 (15.7)
48 (20.2)
8 (8.0)
Tetracycline
61 (11.9)
43 (12.7)
18 (10.3)
24 (7.1)
21 (8.9)
3 (3.0)
Vancomycin
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)

aIn accordance to Performance Standards for Antimicrobial Disk Susceptibility Tests, NCCLS (1998, 1999, 2000, 2002).

bAtleast one antimicrobial agent assayed from a particular class of antibiotics.

cThe intermediate resistant category was included in sensitive category.

d(trimethoprim/sulphamethoxazole).

eMethicillin resistance was confirmed by Oxacillin Salt-agar screening – plate procedure

Dar et al. Annals of Clinical Microbiology and Antimicrobials 2006 5:22   doi:10.1186/1476-0711-5-22